Meeting
2015 ASCO Annual Meeting
Phosphatidylserine targeting antibody in combination with anti-PD-1 antibody treatment activates infiltrating T lymphocytes of the spleen and tumor microenvironment in pre-clinical models of melanoma and breast cancer.
Authors
Xianming Huang
The University of Texas Southwestern, Dallas, TX
Xianming Huang , Jian Gong , Van Nguyen , Shen Yin , Carrie Baldwin , Rolf A. Brekken , Steven King , Jeff Hutchins , Bruce Freimark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunotherapy and Biologic Therapy
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3059)
DOI
10.1200/jco.2015.33.15_suppl.3059
Abstract #
3059
Poster Bd #
385
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
PD1 and CD39 expression on tumor infiltrating lymphocytes in patients with gastric cancer.
First Author: Takafumi Okayama
First Author: Vuong N. Trieu
Poster
2019 ASCO Annual Meeting
Local activator and T cell engager (LocATE) selectively blocks PD-L1 at the cytolytic synapse for deeper responses in multiple myeloma.
First Author: Christian Leisner
Poster
2019 ASCO Annual Meeting
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.
First Author: Michael E. Hurwitz